Certara, Inc.
Certara, Inc. (CERT)
Overview
Certara, Inc. is a global biosimulation and technology-enabled services company serving the pharmaceutical and biotechnology industry, headquartered in the U.S. and operating in 28 countries. The company went public via IPO on December 11, 2020, and for fiscal year 2025 reported revenue of about $421.75 million, up 11.1% year over year, with 1,576 employees (414 holding PhDs or medical degrees). Certara's market capitalization stood around $1.3 billion as of September 2026, down about 30% over the prior year despite continued revenue growth, reflecting broader biotech-sector valuation pressure and a reported negative EPS of -$0.43. Certara's central claim to relevance is stark: according to its own 10-K, customers using its software and services have been associated with 90% or more of all novel FDA drug approvals between 2014 and 2025, underscoring how embedded its tools are in the modern drug-development and regulatory-submission process.
What They Do & How They Make Money
Certara generates revenue by licensing biosimulation software and selling technology-enabled consulting services that help pharmaceutical and biotech companies design, run, and submit drug development programs more efficiently using mathematical and computational modeling rather than purely traditional (and far more expensive) clinical experimentation. Its software spans Simcyp (mechanistic physiologically-based pharmacokinetic modeling), the Phoenix PK/PD suite for pharmacokinetic/pharmacodynamic analysis, and quantitative systems pharmacology (QSP) tools, while its Data & Regulatory Solutions segment includes Pinnacle 21 (clinical data standardization/validation), CoAuthor (generative-AI-assisted regulatory document authoring), and GlobalSubmit (eCTD electronic regulatory submissions). Alongside software licensing, Certara's technology-enabled services arm provides pharmacometrics, clinical pharmacology strategy, and regulatory submission consulting delivered by in-house scientific staff, monetizing both the tools and the expertise needed to use them effectively. The company serves more than 2,600 life sciences organizations across 70 countries, including 38 of the top 40 pharmaceutical R&D spenders, with no single customer exceeding 10% of revenue — a diversified, recurring, enterprise-software-like revenue base layered on top of consulting engagements.
Competitors
- Point-solution modeling vendors including Mathworks, Dassault Systèmes, Ansys, and Simulations Plus, which compete on specific pieces of the biosimulation toolchain.
- ICON's NONMEM division and other CRO-affiliated modeling groups offering competing pharmacometrics services.
- Open-source alternatives (R, PK-Sim) that some smaller biotechs or academic groups use instead of paying for commercial licenses.
- In-house pharmaceutical development teams at large drug companies that build their own modeling capabilities rather than outsourcing to Certara.
Competitive Position
Certara's moat rests on deep regulatory embeddedness: its models and software have become something close to an industry standard accepted by regulators worldwide, and switching away from validated, regulator-familiar tools mid-program carries real risk for a drug sponsor navigating FDA or EMA review. The 2024 acquisition of Chemaxon expanded its footprint further upstream into drug discovery, and the 2025 launch of Certara.AI and 103 new software releases show continued platform investment aimed at widening its lead. The biosimulation market itself, however, is described in Certara's own filings as "competitive and highly fragmented," and large pharmaceutical customers retain the option to build modeling capability in-house, capping how much pricing power Certara can exercise despite its scale and reputation. The combination of high customer switching costs (once a program is built on Certara's validated models), broad diversification across the top pharma R&D spenders, and continued double-digit revenue growth suggests a durable, if not impregnable, competitive position — tempered by a stock price that has more than halved over the trailing year, signaling investor concern about growth durability and margin trajectory in a sector under broader funding pressure.